55362-76-0

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTOXYCARBONYLAMINO-(4-METHOXY-PHENYL)-ACETIC ACID is used as a chemical precursor for the synthesis of pharmaceutical drugs, leveraging its structural properties to create new medications for a range of medical conditions.
Used in Enzyme Inhibition:
In the field of medicinal chemistry, TERT-BUTOXYCARBONYLAMINO-(4-METHOXY-PHENYL)-ACETIC ACID is utilized as an enzyme inhibitor, contributing to the development of treatments that can modulate biological processes at the molecular level.
Used in Inflammation Treatment:
TERT-BUTOXYCARBONYLAMINO-(4-METHOXY-PHENYL)-ACETIC ACID is employed as an anti-inflammatory agent, potentially mitigating the effects of inflammation in various conditions.
Used in Pain Management:
This chemical compound is used in the development of pain management medications, offering a new avenue for treating acute and chronic pain conditions.
Used in Neurodegenerative Disease Treatment:
TERT-BUTOXYCARBONYLAMINO-(4-METHOXY-PHENYL)-ACETIC ACID is used in the research and development of treatments for neurodegenerative diseases, with the aim of slowing disease progression or improving patient outcomes.
Overall, TERT-BUTOXYCARBONYLAMINO-(4-METHOXY-PHENYL)-ACETIC ACID is a versatile and valuable tool in the pharmaceutical industry, with applications that span across multiple therapeutic areas, making it instrumental in the advancement of new therapeutics.

Upstream product

• 124-38-9 carbon dioxide 
• 741259-87-0 tert-butyl (4-methoxyphenyl)(phenylsulfonyl)methylcarbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2540-53-6 2-(4-methoxyphenyl)glycine 
• 1291065-81-0 C₂₅H₄₅NO₃Sn 
• 183671-61-6 (S)-tert-butoxycarbonylamino(4-methoxyphenyl)acetic acid methyl ester 

Downstream Products

• 928162-34-9 C₂₃H₃₁N₃O₇S 
• 380149-34-8 methyl 2-(tert-butoxycarbonylamino)-2-(4-methoxyphenyl)acetate 
• 7479-01-8 O-methyl-tyrosine methyl ester; hydrochloride 
• 1379514-45-0 (R)-quinuclidin-3-yl 2-benzamido-2-(4-methoxyphenyl)acetate 
• 1379514-47-2 (3R)-3-(2-benzamido-2-(4-methoxyphenyl)acetoxy)-1-(2-oxo-2-phenylethyl)-1-azoniabicyclo[2.2.2]octane 2,2,2-trifluoroacetate 
• 1379513-65-1 (3R)-3-(2-(tert-butoxycarbonylamino)-2-(4-methoxyphenyl)acetoxy)-1-(2-oxo-2-phenylethyl)-1-azoniabicyclo[2.2.2]octane bromide 
• 1379513-64-0 (R)-quinuclidin-3-yl 2-(tert-butoxycarbonylamino)-2-(4-methoxyphenyl)acetate 
• 1146981-30-7 allyl 2-(tert-butoxycarbonylamino)-2-(4-methoxyphenyl)acetate 
• 909110-50-5 (benzhydrylidene-amino)-(4-methoxy-phenyl)-acetic acid 2-methyl-allyl ester 
• 1427310-63-1 C₂₄H₂₅N₅O₄ 
• 1427310-62-0 C₂₅H₂₇N₅O₄ 
• 1227360-92-0 C₁₉H₁₇N₅O₂ 
• 1227360-93-1 C₂₀H₁₉N₅O₂ 
• 1427310-61-9 C₂₁H₂₄BrN₃O₅ 

Relevant academic research and scientific papers

Synthesis ofN-Boc-α-amino Acids from Carbon Dioxide by Electrochemical Carboxylation ofN-Boc-α-aminosulfones

Electrochemical reduction ofN-Boc-α-aminosulfones in DMF using an undivided cell equipped with a Pt plate cathode and an Mg rod anode under atmospheric pressure of bubbling carbon dioxide through the solution under constant current conditions resulted in a reductive C-S bond cleavage with elimination of benzenesulfinate ion generating the corresponding anion species followed by fixation of carbon dioxide to give the correspondingN-Boc-α-amino acids in moderate to good yields.

GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS

The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, processes for their preparation, compositions comprising them and therapeutic uses thereof.

GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF

Alkaloid aminoester derivatives according to formula (I) and (VI) act as muscarinic receptor antagonists.

Synthesis of arylglycine and mandelic acid derivatives through carboxylations of α-amido and α-acetoxy stannanes with carbon dioxide

Incorporation reactions of carbon dioxide (CO2) with N-Boc-α-amido and α-acetoxy stannanes were developed using CsF as a mild tin activator. Monoprotected α-amido stannanes could be used, and the corresponding arylglycine derivatives were obtained in moderate-to-high yields under 1 MPa (10 atm) of CO2 pressure. α-Acetoxy stannanes also underwent carboxylation to afford mandelic acid derivatives in excellent yields under ambient CO2 pressure. Both transformations enabled the synthesis of α-tertiary and α-quaternary carboxylic acid derivatives. In addition, the chirality of (S)-N-tert-butylsulfonyl-α- amido stannanes was transferred with up to 90% inversion of configuration at 100 °C.

2-ARYL GLYCINAMIDE DERIVATIVES

The disclosure provides compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their uses in inhibiting β-amyloid peptide ( β-AP) production.

Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors

Molecular modeling and inhibitory potencies of tetrapeptide protease inhibitors of HCV NS3 proposed phenylglycine as a new promising P2 residue. The results suggest that phenylglycine might be capable of interacting with the NS3 (protease-helicase/NTPase)

Derivatives of L- and DL-4-hydroxyphenylglycine

L- and DL-isomers of compounds of the formula STR1 and the pharmaceutically acceptable salts thereof, wherein R is hydrogen or methyl; R1 is alkynyl, alkenyl or cycloalkyl, each having from three to seven carbon atoms or alkyl having from one to six carbon atoms which may optionally be substituted by one or more groups selected from hydroxy, alkoxy, carboxy, amino, monoalkylamino, dialkylamino, phenyl and phenoxy, any such phenyl or phenoxy being optionally substituted with one or more hydroxy, alkyl or alkoxy groups, said alkyl and alkoxy optional substituents having from one to six carbon atoms; provided that R1 is other than 4-hydroxy-α-carboxybenzyl or 4-methoxy-α-carboxybenzyl. Said compounds are useful in treating diseases and conditions characterized by reduced blood flow, oxygen availability or carbohydrate metabolism in the cardiovascular system. The D-isomers of the compounds of formula (II) are substantially inactive in treating such diseases and conditions.